SHIM
TAK icon

Stone House Investment Management’s Takeda Pharmaceutical TAK Stock Holding History

Stone House Investment Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.33K Sell
457
-620
-58% -$10.3K ﹤0.01% 488
2026
Q1 		$19.9K Buy
+1,077
New +$18.9K ﹤0.01% 276

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Stone House Investment Management's TAK Position: Q2 2026 in Review

Stone House Investment Management reduced its Takeda Pharmaceutical (TAK) stake by 58% in Q2 2026, selling an estimated $10.3K and leaving 457 shares worth $7.33K. The position accounts for ﹤0.01% of the portfolio, ranked #488.

Stone House Investment Management first reported a position in TAK in Q1 2026 and has held it in 2 quarters since. The position peaked at $19.9K in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Stone House Investment Management held 457 shares of Takeda Pharmaceutical worth $7.33K as of Q2 2026.
  • Stone House Investment Management sold 620 Takeda Pharmaceutical shares in Q2 2026, an estimated $10.3K.
  • Takeda Pharmaceutical made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #488 holding.
  • Stone House Investment Management first reported a position in Takeda Pharmaceutical in Q1 2026 and has held it in 2 quarters since.
  • Stone House Investment Management's Takeda Pharmaceutical position peaked at $19.9K in Q1 2026.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.